Univest
Univest
  • Markets

Alembic Pharma Share Price: 12.3% CAGR in 3 Years as the Vadodara-Based Drug Maker Compares With Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals

  • November 19, 2026
  • Posted by: Kunal Singla
  • Category: Best Stocks
No Comments
Alembic Pharma Share Price: 12.3% CAGR in 3 Years as the Vadodara-Based Drug Maker Compares With Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals

Table of Contents

Toggle
  • Alembic Pharma Share Price: 12.3% CAGR in 3 Years as the Vadodara-Based Drug Maker Compares With Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals
    • How Much Has the Alembic Pharma Share Price Returned in 3 Years?
    • Alembic Pharma vs Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals: 3-Year CAGR Compared
    • Valuation and Quality Compared
    • What Is Driving the Alembic Pharma Stock?
    • How the Established Players Stack Up
    • What Should Investors Track Next?
    • How to Compare Pharma Stocks Yourself
    • A Low-Multiple Drug Maker Beside Three Larger Peers
    • Frequently Asked Questions
      • What is the Alembic Pharma share price today?
      • What is the 3-year CAGR of the Alembic Pharma stock?
      • Is Alembic Pharma better than Lupin?
      • What does Alembic Pharmaceuticals do?
      • Is the Alembic Pharma stock debt free?
      • Is Alembic Pharma expensive compared with the industry?
      • Which pharma stock gave the highest return in 3 years?
      • How do I calculate CAGR for a stock?

Alembic Pharma Share Price: 12.3% CAGR in 3 Years as the Vadodara-Based Drug Maker Compares With Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals

Alembic Pharma previous close Rs 1,044.35. 3-year CAGR 12.3%. Up 1.4x since 17 Nov 2023. ROE 14.20%. Market cap Rs 20,512 crore.

Quick Answer

The Alembic Pharma share price closed at Rs 1,044.35 on 18 November 2026, a compounded annual return of 12.3% over three years. That compares with Zydus Lifesciences at 23.6%, Lupin at 18.1% and Glenmark Pharmaceuticals at 50.5%. The company has a market cap of Rs 20,512 crore and a P/E of 24.43 against an industry P/E of 40.12.

The Alembic Pharma share price closed at Rs 1,044.35 on 18 November 2026 and has compounded at 12.3% a year over three years. Alembic Pharmaceuticals, based in Vadodara, makes generic medicines, specialty drugs and active ingredients for India and export markets.

This article places that return beside Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals. We calculate the three-year CAGR for all four and set the results next to market cap, valuation, return on equity and debt, using prices adjusted for corporate actions.

Click Here – Get Free Investment Predictions

How Much Has the Alembic Pharma Share Price Returned in 3 Years?

The Alembic Pharma stock closed at Rs 737.30 on 17 November 2023 and at Rs 1,044.35 on 18 November 2026. Rs 1 lakh invested three years ago would have grown to about Rs 1.42 lakh, which is a CAGR of 12.3%. This is a price return and leaves out dividends.

CAGR condenses a bumpy three-year ride into one yearly number, which is why it is the fairest way to compare companies of different sizes. A stock such as Alembic Pharma can look spectacular on a chart and still have earned a modest yearly return, so the compounded figure keeps the comparison honest.

Pharma shares move with product launches, approvals and currency, so a three-year window captures several cycles. The Alembic Pharma share price has risen steadily while its valuation stayed below the sector average.

Alembic Pharma vs Zydus Lifesciences, Lupin and Glenmark Pharmaceuticals: 3-Year CAGR Compared

The table ranks the companies by three-year CAGR. Prices on 17 November 2023 are adjusted for splits and bonuses, and the latest figures are the previous close on 18 November 2026.

Company Close on 17 Nov 2023 Previous close (18 Nov 2026) Price multiple 3-year CAGR
Glenmark Pharmaceuticals Rs 775.95 Rs 2,646.10 3.4x 50.5%
Zydus Lifesciences Rs 636.55 Rs 1,202.00 1.9x 23.6%
Lupin Rs 1,196.30 Rs 1,971.90 1.6x 18.1%
Alembic Pharmaceuticals Rs 737.30 Rs 1,044.35 1.4x 12.3%

The Alembic Pharma stock ranks fourth of the four at 12.3%. The companies ahead are Glenmark Pharmaceuticals (50.5%), Zydus Lifesciences (23.6%) and Lupin (18.1%). By market cap the company ranks fourth of the four at Rs 20,512 crore. Zydus Lifesciences is the largest of the four by market cap, so Alembic is the smallest company in this group.

Look at the Alembic Pharma share price alongside the peers as a snapshot of the last three years. It describes what happened, and valuation and earnings will decide what happens next.

Valuation and Quality Compared

Company Market cap P/E Industry P/E ROE Debt to equity
Zydus Lifesciences Rs 1,19,202 crore 27.71 40.12 15.10% 0.50
Lupin Rs 90,039 crore 17.24 40.12 21.65% 0.26
Glenmark Pharmaceuticals Rs 74,931 crore 51.63 40.12 18.07% 0.13
Alembic Pharmaceuticals Rs 20,512 crore 24.43 40.12 14.20% 0.26

By market cap, Zydus Lifesciences is the largest of the group at Rs 1,19,202 crore, while the Alembic Pharma stock stands at Rs 20,512 crore, about 17% of that size. On earnings, Alembic Pharma shares trade at a P/E of 24.43 against an industry P/E of 40.12, a discount of about 39% to the sector, which leaves room if earnings keep growing. Peer multiples are Zydus Lifesciences at 27.71, Lupin at 17.24 and Glenmark Pharmaceuticals at 51.63.

Return on equity is 14.20% for the Alembic Pharma stock, which ranks fourth among the four, and debt to equity stands at 0.26. Trailing EPS is Rs 42.72. Alembic trades at a P/E of 24.43 against an industry P/E of 40.12, with a price to book of 3.45. That is the second lowest P/E in the group, so the market asks less for each rupee of earnings.

What Is Driving the Alembic Pharma Stock?

Alembic sells generic formulations in the United States and India, along with specialty products and active pharmaceutical ingredients. The mix gives it exposure to both regulated export markets and the domestic branded market.

The company earns an ROE of 14.20% and carries a debt to equity of 0.26, which is the second highest in the group. Its P/E of 24.43 sits well below the industry P/E of 40.12.

Investors who follow the Alembic Pharma share price usually track US generic launches, India sales growth, plant approvals and quarterly operating margin.

How the Established Players Stack Up

Zydus Lifesciences is an Ahmedabad-based drug maker with generics, branded medicines and a vaccines business. It compounded at 23.6% a year, on a market cap of Rs 1,19,202 crore and an ROE of 15.10%.

Lupin is a Mumbai-based drug maker with a strong presence in respiratory and cardiovascular medicines. It compounded at 18.1% a year, on a market cap of Rs 90,039 crore and an ROE of 21.65%.

Glenmark Pharmaceuticals is a Mumbai-based drug maker with a presence in dermatology and respiratory therapies. It compounded at 50.5% a year, on a market cap of Rs 74,931 crore and an ROE of 18.07%.

What Should Investors Track Next?

Three things are worth watching on the Alembic Pharma share price. First, product launches and approvals in the United States. Second, growth in the India business. Third, operating margin in the next quarterly result.

At a P/E of 24.43 the stock trades well below the industry P/E of 40.12, which leaves room if earnings keep growing. US pricing can change quickly, so follow each result closely.

Check the Univest Screener for live fundamentals of pharma stocks

How to Compare Pharma Stocks Yourself

You can repeat this exercise for any pair of stocks, including the Alembic Pharma stock against its peers. Note the adjusted closing price on the base date, take the latest close, divide one by the other, raise the result to the power of one third and subtract one. Then place the CAGR next to market cap, P/E against the industry P/E, ROE and debt to equity. Benchmark the result against the Nifty 50 as well, so you know whether the stock beat the broader market.

A stock that scores well on growth but weakly on quality, or the reverse, deserves closer study before it enters a portfolio. When tracking the Alembic Pharma share price, the same four checks give a more complete picture than price alone.

Download the Univest iOS App or Univest Android App to track the Alembic Pharma share price and compare pharma stocks live.

A Low-Multiple Drug Maker Beside Three Larger Peers

The Alembic Pharma share price compounded at 12.3% a year over three years, against 50.5% for Glenmark, 23.6% for Zydus and 18.1% for Lupin. It trades at a P/E of 24.43, against an industry P/E of 40.12.

Glenmark Pharmaceuticals brings the fastest return, Lupin brings the highest ROE and Lupin brings the lowest P/E. Alembic has a smaller market cap than the other three and a P/E well below the industry average.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

What is the Alembic Pharma share price today?

Ans. Alembic Pharmaceuticals closed at Rs 1,044.35 on 18 November 2026, according to NSE data. It has a market cap of Rs 20,512 crore and a P/E of 24.43. Check live quotes before acting, as prices change every trading day.

What is the 3-year CAGR of the Alembic Pharma stock?

Ans. Alembic Pharmaceuticals delivered a price CAGR of 12.3% over three years, moving from Rs 737.30 on 17 November 2023 to Rs 1,044.35 on 18 November 2026. The figure excludes dividends and uses adjusted closing prices.

Is Alembic Pharma better than Lupin?

Ans. Lupin delivered the higher three-year CAGR at 18.1% against 12.3% for Alembic Pharma. Lupin has the larger market cap at Rs 90,039 crore against Rs 20,512 crore for Alembic Pharma. Lupin earns the higher ROE at 21.65% against 14.20%. Lupin trades at the lower P/E of 17.24 against 24.43. The better choice depends on whether you weigh recent return, size, profitability or valuation most.

What does Alembic Pharmaceuticals do?

Ans. Alembic Pharmaceuticals Limited is a Vadodara-based pharmaceutical company that makes generic medicines, specialty drugs and active ingredients for India and global markets.

Is the Alembic Pharma stock debt free?

Ans. The debt to equity ratio of the Alembic Pharma stock is 0.26 and its return on equity is 14.20%. Always check the latest balance sheet for current figures, as debt levels change with expansion plans.

Is Alembic Pharma expensive compared with the industry?

Ans. Alembic Pharma trades at a P/E of 24.43 against an industry P/E of 40.12. A higher multiple reflects expectations of faster growth, which the company must deliver through earnings.

Which pharma stock gave the highest return in 3 years?

Ans. Among the companies compared here, Glenmark Pharmaceuticals delivered the highest three-year CAGR at 50.5%, followed by Zydus Lifesciences at 23.6%. Past returns do not guarantee future performance.

How do I calculate CAGR for a stock?

Ans. Divide the latest price by the starting price, raise the result to the power of one divided by the number of years, and subtract one. Multiply by 100 for a percentage. Use split and bonus adjusted prices for accurate results.



Alembic Pharma share price Alembic Pharma vs Lupin Alembic Pharmaceuticals stock pharma stocks 3 year return
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply